Alzai Health (FRA:H2F) Return-on-Tangible-Asset: -631.91% (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:H2F Alzai Health Corp FRA:H2F
9 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is Alzai Health Return-on-Tangible-Asset?

Alzai Health FRA:H2F -1.62% 9 Return-on-Tangible-Asset is -631.91% as of Jan. 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Alzai Health ranks worse than 96.04% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alzai Health's annualized Net Income for the quarter that ended in Jan. 2026 was €-3.62 Mil. Alzai Health's average total tangible assets for the quarter that ended in Jan. 2026 was €0.57 Mil. Therefore, Alzai Health's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2026 was -631.91%.

The historical rank and industry rank for Alzai Health's Return-on-Tangible-Asset or its related term are showing as below:

FRA:H2F' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -355.25   Med: 0   Max: 0
Current: -355.25

FRA:H2F's Return-on-Tangible-Asset is ranked worse than
96.04% of 1415 companies
in the Biotechnology industry
Industry Median: -35.49 vs FRA:H2F: -355.25

Alzai Health  (FRA:H2F) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Alzai Health Return-on-Tangible-Asset Related Terms


Alzai Health Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Alzai Health's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health Return-on-Tangible-Asset Chart

Alzai Health Annual Data
Trend Apr25
Return-on-Tangible-Asset
0.00

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
Return-on-Tangible-Asset 0.00 -525.23 -220.62 -290.40 -631.91

FRA:H2F vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Alzai Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alzai Health Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alzai Health's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Alzai Health's Return-on-Tangible-Asset falls into.


FRA:H2F
9GF Score
Alzai Health Corp FRA:H2F
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health Return-on-Tangible-Asset Calculation

Alzai Health's annualized Return-on-Tangible-Asset for the fiscal year that ended in Apr. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Apr. 2025 )  (A: . 20 )(A: Apr. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Apr. 2025 )  (A: . 20 )(A: Apr. 2025 )
=/( (+)/ )
=/
= %

Alzai Health's annualized Return-on-Tangible-Asset for the quarter that ended in Jan. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-3.624/( (0.576+0.571)/ 2 )
=-3.624/0.5735
=-631.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jan. 2026) net income data.

What does a Return-on-Tangible-Asset of -631.91% mean?
Alzai Health (FRA:H2F) has a Return-on-Tangible-Asset of -631.91% as of Jan. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alzai Health and its competitors. According to the industry distribution chart, Alzai Health ranks #1359 out of 1415 companies in the Biotechnology industry, placing it in the top 96%.
Is Alzai Health's Return-on-Tangible-Asset too high?
Alzai Health's current Return-on-Tangible-Asset is -631.91%. Based on the distribution chart, Alzai Health ranks #1359 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzai Health ranks #1359 out of 1415 companies for Return-on-Tangible-Asset. This places Alzai Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Alzai Health and its competitors. Alzai Health's current Return-on-Tangible-Asset is -631.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current Return-on-Tangible-Asset of -631.91%. The current Return-on-Tangible-Asset is -631.91%. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current Return-on-Tangible-Asset is -631.91% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Other Exchanges ALZI:Canada
Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for FRA:H2F

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price